vs

Side-by-side financial comparison of Carlyle Group Inc. (CG) and ResMed (RMD). Click either name above to swap in a different company.

Carlyle Group Inc. is the larger business by last-quarter revenue ($1.9B vs $1.4B, roughly 1.3× ResMed). ResMed runs the higher net margin — 27.6% vs 18.8%, a 8.8% gap on every dollar of revenue. On growth, Carlyle Group Inc. posted the faster year-over-year revenue change (84.1% vs 11.0%). Over the past eight quarters, Carlyle Group Inc.'s revenue compounded faster (66.2% CAGR vs 7.9%).

The Carlyle Group Inc. is an American multinational company with operations in private equity, alternative asset management and financial services. As of 2023, the company had $426 billion of assets under management.

ResMed Inc. is a medical equipment company based in San Diego, California, and founded in Australia. It primarily provides cloud-connectable medical devices for the treatment of sleep apnea, chronic obstructive pulmonary disease (COPD), and other respiratory conditions. Resmed produced hundreds of thousands of ventilators and bilevel devices to help treat the respiratory symptoms of patients with COVID-19.

CG vs RMD — Head-to-Head

Bigger by revenue
CG
CG
1.3× larger
CG
$1.9B
$1.4B
RMD
Growing faster (revenue YoY)
CG
CG
+73.2% gap
CG
84.1%
11.0%
RMD
Higher net margin
RMD
RMD
8.8% more per $
RMD
27.6%
18.8%
CG
Faster 2-yr revenue CAGR
CG
CG
Annualised
CG
66.2%
7.9%
RMD

Income Statement — Q4 FY2025 vs Q4 FY2026

Metric
CG
CG
RMD
RMD
Revenue
$1.9B
$1.4B
Net Profit
$358.1M
$392.6M
Gross Margin
61.8%
Operating Margin
24.3%
34.6%
Net Margin
18.8%
27.6%
Revenue YoY
84.1%
11.0%
Net Profit YoY
69.8%
13.9%
EPS (diluted)
$0.96
$2.68

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CG
CG
RMD
RMD
Q2 26
$1.4B
Q4 25
$1.9B
$1.4B
Q3 25
$332.7M
$1.3B
Q2 25
$1.6B
$1.3B
Q1 25
$973.1M
$1.3B
Q4 24
$1.0B
$1.3B
Q3 24
$2.6B
$1.2B
Q2 24
$1.1B
$1.2B
Net Profit
CG
CG
RMD
RMD
Q2 26
$392.6M
Q4 25
$358.1M
$392.6M
Q3 25
$900.0K
$348.5M
Q2 25
$319.7M
$379.7M
Q1 25
$130.0M
$365.0M
Q4 24
$210.9M
$344.6M
Q3 24
$595.7M
$311.4M
Q2 24
$148.2M
$292.2M
Gross Margin
CG
CG
RMD
RMD
Q2 26
61.8%
Q4 25
61.8%
Q3 25
61.5%
Q2 25
60.8%
Q1 25
59.3%
Q4 24
58.6%
Q3 24
58.6%
Q2 24
58.5%
Operating Margin
CG
CG
RMD
RMD
Q2 26
34.6%
Q4 25
24.3%
34.6%
Q3 25
25.8%
33.4%
Q2 25
28.0%
33.7%
Q1 25
17.6%
33.0%
Q4 24
25.7%
32.5%
Q3 24
29.9%
31.6%
Q2 24
20.5%
31.2%
Net Margin
CG
CG
RMD
RMD
Q2 26
27.6%
Q4 25
18.8%
27.6%
Q3 25
0.3%
26.1%
Q2 25
20.3%
28.2%
Q1 25
13.4%
28.3%
Q4 24
20.4%
26.9%
Q3 24
22.6%
25.4%
Q2 24
13.9%
23.9%
EPS (diluted)
CG
CG
RMD
RMD
Q2 26
$2.68
Q4 25
$0.96
$2.68
Q3 25
$0.00
$2.37
Q2 25
$0.87
$2.58
Q1 25
$0.35
$2.48
Q4 24
$0.56
$2.34
Q3 24
$1.63
$2.11
Q2 24
$0.40
$1.97

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CG
CG
RMD
RMD
Cash + ST InvestmentsLiquidity on hand
$2.0B
$1.4B
Total DebtLower is stronger
$663.8M
Stockholders' EquityBook value
$7.1B
$6.3B
Total Assets
$29.1B
$8.5B
Debt / EquityLower = less leverage
0.11×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CG
CG
RMD
RMD
Q2 26
$1.4B
Q4 25
$2.0B
$1.4B
Q3 25
$2.2B
$1.4B
Q2 25
$1.3B
$1.2B
Q1 25
$1.2B
$932.7M
Q4 24
$1.3B
$521.9M
Q3 24
$1.4B
$426.4M
Q2 24
$914.8M
$238.4M
Total Debt
CG
CG
RMD
RMD
Q2 26
$663.8M
Q4 25
$403.9M
Q3 25
$408.7M
Q2 25
$658.4M
Q1 25
$663.1M
Q4 24
$662.9M
Q3 24
$667.6M
Q2 24
$697.3M
Stockholders' Equity
CG
CG
RMD
RMD
Q2 26
$6.3B
Q4 25
$7.1B
$6.3B
Q3 25
$6.8B
$6.1B
Q2 25
$6.7B
$6.0B
Q1 25
$6.4B
$5.5B
Q4 24
$6.3B
$5.3B
Q3 24
$6.3B
$5.2B
Q2 24
$5.7B
$4.9B
Total Assets
CG
CG
RMD
RMD
Q2 26
$8.5B
Q4 25
$29.1B
$8.5B
Q3 25
$27.1B
$8.3B
Q2 25
$25.1B
$8.2B
Q1 25
$24.1B
$7.6B
Q4 24
$23.1B
$7.1B
Q3 24
$22.7B
$7.2B
Q2 24
$22.3B
$6.9B
Debt / Equity
CG
CG
RMD
RMD
Q2 26
0.11×
Q4 25
0.06×
Q3 25
0.07×
Q2 25
0.11×
Q1 25
0.12×
Q4 24
0.13×
Q3 24
0.13×
Q2 24
0.14×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CG
CG
RMD
RMD
Operating Cash FlowLast quarter
$-1.2B
Free Cash FlowOCF − Capex
$-1.2B
FCF MarginFCF / Revenue
-65.1%
Capex IntensityCapex / Revenue
2.2%
Cash ConversionOCF / Net Profit
-3.34×
TTM Free Cash FlowTrailing 4 quarters
$-3.4B

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CG
CG
RMD
RMD
Q2 26
Q4 25
$-1.2B
$339.7M
Q3 25
$-1.6B
$457.3M
Q2 25
$-168.8M
$538.8M
Q1 25
$-352.1M
$578.7M
Q4 24
$-352.8M
$308.6M
Q3 24
$791.9M
$325.5M
Q2 24
$-1.3B
$440.1M
Free Cash Flow
CG
CG
RMD
RMD
Q2 26
Q4 25
$-1.2B
$311.2M
Q3 25
$-1.6B
$414.4M
Q2 25
$-186.3M
$508.2M
Q1 25
$-368.8M
$557.9M
Q4 24
$-379.5M
$288.0M
Q3 24
$772.8M
$307.7M
Q2 24
$-1.3B
$415.2M
FCF Margin
CG
CG
RMD
RMD
Q2 26
Q4 25
-65.1%
21.9%
Q3 25
-475.7%
31.0%
Q2 25
-11.8%
37.7%
Q1 25
-37.9%
43.2%
Q4 24
-36.8%
22.5%
Q3 24
29.3%
25.1%
Q2 24
-120.4%
33.9%
Capex Intensity
CG
CG
RMD
RMD
Q2 26
Q4 25
2.2%
2.0%
Q3 25
7.0%
3.2%
Q2 25
1.1%
2.3%
Q1 25
1.7%
1.6%
Q4 24
2.6%
1.6%
Q3 24
0.7%
1.5%
Q2 24
1.7%
2.0%
Cash Conversion
CG
CG
RMD
RMD
Q2 26
Q4 25
-3.34×
0.87×
Q3 25
-1732.78×
1.31×
Q2 25
-0.53×
1.42×
Q1 25
-2.71×
1.59×
Q4 24
-1.67×
0.90×
Q3 24
1.33×
1.05×
Q2 24
-8.57×
1.51×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CG
CG

Fund Management Fee$606.8M32%
Other$528.7M28%
Global Private Equity Segment$307.3M16%
Global Credit Segment$238.0M13%
Carlyle Alp Invest Segment$124.6M7%
Incentive Fee$55.4M3%
Fee Related Performance Revenues$29.2M2%
Investment Advice$11.1M1%

RMD
RMD

Segment breakdown not available.

Related Comparisons